• Memantine represents an effective treatment for AD patients with APS in the UK and is an efficient use of NHS resources.
INTRODUCTION
• Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder which affects around 465,000 people in the UK. 1
• Of the total AD patient population, 31% and 21% of US patients are expected to be in the moderate and severe stages of the disease respectively. 2
• The median survival from diagnosis of AD is approximately 6 years (range 1-16 years), with about one-third of the time being spent in the severe stage. 3
• An important sub-group of AD patients are those with agitation/aggression or psychotic symptoms (APS). Data from the LASER-AD study in the UK suggest that around 45% of moderate to severe AD patients fall into this category. 4
• The total economic burden of dementia in Europe is estimated to be €55-€66 billion annually based on 2003 values. 5 In the UK alone, the estimated direct cost of AD is between £7.06 billion and £14.93 billion. 6
• Postponing or stabilising decline in any of the key symptoms represents a meaningful benefit to both patients and their carers.
• • Each Markov cycle was 1 month, yielding 60 cycles over the 5 year period.
• Effectiveness estimates came from a metaanalysis of six randomised clinical trials. 8
• Transition probabilities, baseline characteristics, resource utilisation, health utility weights and mortality rates were derived from the LASER-AD study. • The clinical benefits of memantine have been found to be greater in the APS sub-population of AD patients. 10 This has therefore been reflected in the 'memantine effect' input values for the model.
• Utility values were derived from mapping of healthcare questionnaire results to the EQ-5D dimensions. This allowed researchers to calculate the utility values for the three health states of the model.
Costs
• Costs included: routine patient management, hospitalisation, social community services, institutionalisation and medications (see Table 1 ).
• Treatment costs for memantine were £64.80 per cycle + £126.36 for initial consultation and £35 every 6 cycles for subsequent GP monitoring visits. • The drug acquisition cost of ChEIs were not taken into account as it was assumed that patients in both groups would have the same level of ChEI usage.
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Sensitivity analysis
• The model underwent extensive stochastic and one-way deterministic analyses across clinical inputs, discount rates (0% and 6%), costs (±30%) and utilities.
RESULTS
Base-case results
Memantine was associated with:
• Prolongation of time to FTC by 11.2 weeks compared to standard care • A gain in QALYs of 0.07 over standard care
• A decrease in costs of £4,970 (€5,930) compared to standard care.
Memantine is a dominant treatment strategy compared to standard care. 
Sensitivity Analyses Results
Results of the sensitivity analyses confirm the robustness of the base-case analysis results. The probabilities of the memantine strategy being superior to the standard care strategy in all probabilistic sensitivity analyses are summarised in Table 3 below. 
COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS WITH AGITATION, AGGRESSION AND PSYCHOSIS -THE UK EXAMPLE
OBJECTIVES
To assess the cost-effectiveness of memantine in the APS patient subgroup, in the UK setting.
